FIELD: biotechnology.
SUBSTANCE: compounds have the general formula: X1-X2-X3-Pro-X4-Pro-X5, where X1 is selected from H, Ac-, Palm-; X2 is selected from Trp, Tyr; X3 is selected from Trp, Tyr; X4 is selected from Lys, Orn, Dbu, Dpr, Arg; X5 is selected from-OH, -NH2, -OCH3, -OC2H5, -NH-C6H5. This compound can be represented in the form of retroisomer.
EFFECT: invention enables to block selectively the muscle nicotinic acetylcholine receptor with high efficiency.
12 cl, 7 dwg, 1 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
METASTIN DERIVATIVES AND APPLICATION THEREOF | 2006 |
|
RU2430107C2 |
METASTIN DERIVATIVES AND USE THEREOF | 2007 |
|
RU2454425C2 |
PEPTIDE COMPOSITIONS | 2014 |
|
RU2725150C2 |
APPLICATION OF MELANOCORTIN FOR TREATING INSULIN SENSITIVITY | 2008 |
|
RU2453328C2 |
METHOD FOR TREATMENT OF DISORDERS ASSOCIATED WITH MELANOCORTIN 4 RECEPTOR PATH | 2016 |
|
RU2785889C1 |
ALPHA- AND GAMMA-MSH ANALOGUES | 2013 |
|
RU2668791C2 |
MELANOCORTIN RECEPTOR LIGANDS | 2006 |
|
RU2380372C2 |
MELANOCORTIN RECEPTOR LIGANDS | 2006 |
|
RU2439079C2 |
PEPTIDE VECTORS | 2004 |
|
RU2361876C2 |
PEPTIDE HAVING LYNX1 PROTEIN ACTIVITY (EMBODIMENTS), PHARMACEUTICAL COMPOSITION FOR TREATING ANXIETY DISORDERS AND DEPRESSION OR CORRECTION OF COGNITIVE DISORDERS IN NEURODEGENERATIVE DISEASES, CONTAINING SAID PEPTIDE, AND METHOD OF TREATING AND CORRECTING SAID DISORDERS | 2020 |
|
RU2734649C1 |
Authors
Dates
2014-07-27—Published
2013-01-21—Filed